Stem Cell Therapy for Stroke in Thailand: Evidence, Risks and Questions to Ask

1. A technology name in a comparison table is not proof of benefit

When a facility comparison mentions stem cells alongside robotics or brain stimulation, families may read the list as a ranking of treatment strength. It is not. These are different interventions with different evidence, purposes and risks. The availability of an additional treatment does not establish that a programme produces better walking recovery.

Start with the questions in our inpatient comparison guide: who assists with transfers and bathroom use, how much therapy is planned, what nursing support is available, and how care continues at home. Then evaluate any proposed cell treatment separately. Keep unconfirmed claims marked as awaiting clarification rather than counting them as an advantage.

Compare inpatient stroke rehabilitation facilities abroad

2. Does stem cell therapy work for stroke patients?

Researchers have studied cell transplantation after stroke, but “stem cell therapy” is not one standard treatment. Cell source, preparation, dose, route, timing and patient selection can differ. A finding from one protocol cannot be assumed to apply to another—or from ischaemic stroke to haemorrhagic stroke.

The Cochrane review of stem cell transplantation for ischaemic stroke found low- to very-low-certainty evidence and called for better trials. This supports caution, not a promise of restored brain tissue or independent walking. The review is a foundation for understanding uncertainty, not an exhaustive account of every subsequent trial. Ask the clinician for current published evidence for the exact proposed protocol. [1]

A patient story can describe someone’s experience, but cannot separate the effects of a procedure from rehabilitation, other treatment or recovery over time. Ask whether a study used a comparison group, how many people participated, whether outcomes concerned everyday function, and how long safety was monitored. A preliminary signal of benefit is not the same as established clinical effectiveness.

3. Check approval for the treatment—not just the building

The US FDA warns that regenerative medicine products have not been approved to treat neurological disorders such as stroke. This statement describes US regulation; it does not determine a product’s legal status in Thailand. Approval for a different condition, hospital accreditation or a physician’s licence does not establish approval of a particular cell product for stroke. [2]

For treatment in Thailand, request written documentation identifying the product, treating facility, responsible doctor and applicable Thai regulatory requirements or permissions. If it is research, request ethics approval, the trial registration identifier and the consent document. A trial listing alone does not prove regulatory approval, efficacy or endorsement. The FDA specifically cautions against interpreting database listings as approval. [2]

This guide does not verify a Thai approval, a cell source, an administration route or a trial registration for Sanpiti’s offering. Those details must be confirmed for the specific proposed treatment before a family agrees. If the evidence or documentation is unclear, seek an independent medical opinion before paying or travelling.

4. What risks should a family discuss?

Risks depend on the product and how it is administered, as well as the patient’s medical condition. FDA warnings about unapproved regenerative medicine products describe infection, unwanted immune reactions and tumour formation among potential harms. These are general warnings—not measured risk rates for a specific Sanpiti protocol. Do not assume that cells described as “natural” or obtained from the patient are risk-free. [3]

Ask how cells are sourced, processed, tested and stored; what procedure-related risks apply; and how adverse events are detected and treated. Discuss medicines, previous reactions, infections and other conditions with the treating doctor. Do not stop antiplatelet, anticoagulant or other stroke medicines yourself in preparation for a procedure.

Consent should explain uncertainty, alternatives—including rehabilitation without the adjunct—and what happens if there is no improvement or a complication. The family should have time to review it in a language they understand, without pressure to book immediately.

• Who handles a complication during treatment and after discharge?
• What warning symptoms need urgent attention?
• How long is follow-up, and what records will the home clinician receive?
• Which complication and follow-up charges remain the family’s responsibility?

5. Keep walking and daily living support at the centre of the plan

Established stroke rehabilitation addresses the tasks the patient needs to perform: sitting, standing, safe transfers, walking, dressing, toileting, communication and swallowing when indicated. NICE recommends needs-based multidisciplinary rehabilitation, repetitive task training and walking training tailored to the person. It is a UK guideline reference, not a guarantee about the timetable at any international facility. [4]

Compare physiotherapy, occupational therapy, speech and swallowing support as clinically needed, plus nursing between sessions. Ask for session lengths, treatment days, rest breaks and reassessment dates. An advertised number of appointments does not establish active treatment hours.

If a cell-based adjunct is proposed, ask whether preparation or recovery will interrupt the rehabilitation timetable and how the team will adapt it safely. Agree functional goals that can be reviewed, such as transferring to a commode with a stated assistance level. Do not judge the programme solely by whether a procedure was administered.

6. How Sanpiti presents stem cell therapy

Sanpiti describes stem cell therapy as an adjunct considered alongside intensive rehabilitation, not as a cure or a substitute for therapy. The attending physical medicine and rehabilitation (PM&R) physician evaluates the individual after reviewing the diagnosis, brain imaging and medical history. Assessment may lead to a discussion of an adjunct; it is not automatic eligibility or a guarantee that treatment will be recommended.

Cerebrolysin and stem cell therapy are distinct interventions. The presence of both on a technology list does not establish that combining them is necessary, effective or appropriate for everyone. Request a separate rationale, evidence discussion and risk explanation for each proposed treatment.

No stem cell or Cerebrolysin price is quoted in this guide. Any proposed adjunct is itemised separately after clinical assessment. Ask for the written treatment plan, product and oversight documentation, consent and follow-up arrangements before making a decision. This is provider-authored educational information, not an independent endorsement or a physician-reviewed individual recommendation.

Hospital-based rehabilitation at Jin Wellbeing

International stroke rehabilitation in Thailand

7. Questions to resolve before travelling to Thailand

Have the treating team assess medical stability and travel requirements, and obtain receiving-team acceptance before booking. A treatment appointment is not clearance to fly. Plan airport assistance, transfers, medicines, accessible accommodation and caregiver support according to the patient’s actual needs.

CDC guidance on medical tourism emphasises checking credentials and risks, obtaining medical records and arranging follow-up. Before departure, agree who will manage rehabilitation and any treatment-related problems after returning home. Ask the insurer explicitly about investigational treatments, complications, extended stays and medical evacuation; do not assume coverage. [5]

• What exact product, cell source and administration route are proposed?
• What published evidence applies to this patient’s stroke type and stage?
• What local authorisation or research oversight applies?
• What are the realistic uncertainties, alternatives and risks?
• Will rehabilitation continue, with which goals and schedule?
• Who monitors safety after the family returns home?
• Can all care, procedure and follow-up charges be reviewed in writing?

Admission and travel planning